Please login to the form below

Not currently logged in
Email:
Password:

AZ's Lisa Anson elected president of ABPI

She takes up the lead role from April 2017

AZ Lisa AnsonThe Association of the British Pharmaceutical Industry has elected Lisa Anson to serve as its president from the end of April next year.

Anson joined the ABPI board in 2012 and has since overseen a number of schemes for the association, including the implementation of the Pharmaceutical Pricing Regulation Scheme.

Currently serving as president of AstraZeneca UK and Ireland, Anson has held several senior management positions at the firm, including vice president of emerging brands.

She brings further pharmaceutical management experience from California-based Salick Health Care, where she was vice president of strategy, and management consultancy expertise from KPMG.

Mike Thompson, the ABPI's chief executive said: “The unanimous decision by the ABPI board to elect Lisa Anson as president shows the esteem in which she is held.

“As a high profile president of AstraZeneca UK and Ireland her knowledge and experience will be valuable as we head into what is arguably the UK pharmaceutical industry's most challenging era to date.

“Lisa will play a leading role as we negotiate the future of our industry outside the European Union and as we work with government to build an industrial strategy with life-sciences at its heart.

“Speaking on behalf of the board and all staff at the ABPI, we very much look forward to working with Lisa.”

14th December 2016

From: Healthcare

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics